{"description":"Any sign or symptom that occurs after written informed consent provided. For TEAE from first dosing (single administration, Day 1) up to last follow-up visit or until the event has resolved to baseline grade or better or the event was assessed stable by the investigator or the patient was lost to follow-up or withdrew consent.","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":5,"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"EG000","otherNumAffected":0,"otherNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"title":"Breast"},{"deathsNumAffected":0,"deathsNumAtRisk":5,"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"EG001","otherNumAffected":1,"otherNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"title":"Prostate"},{"deathsNumAffected":0,"deathsNumAtRisk":5,"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"EG002","otherNumAffected":3,"otherNumAtRisk":5,"seriousNumAffected":0,"seriousNumAtRisk":5,"title":"Colorectal"},{"deathsNumAffected":0,"deathsNumAtRisk":3,"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"EG003","otherNumAffected":3,"otherNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"title":"Non-Small Cell Lung Cancer (NSCLC)"},{"deathsNumAffected":0,"deathsNumAtRisk":1,"description":"All eligible participants were to receive recommended dose of \\[68Ga\\]-NeoBOMB1 of 3 Mega Becquerel (MBq)/Kg (+/- 10%) \\[but not more than 250 and not less than 150 MBq. The maximum peptide mass administered was 50 microgram (µg)\\].","id":"EG004","otherNumAffected":1,"otherNumAtRisk":1,"seriousNumAffected":1,"seriousNumAtRisk":1,"title":"Small-Cell Lung Cancer (SCLC)"}],"frequencyThreshold":"5","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":1}],"term":"Anaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":1}],"term":"Hyperfibrinogenaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":1,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":1}],"term":"Hyperparathyroidism"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":1}],"term":"Post procedural constipation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":1}],"term":"Procedural pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":1}],"term":"Blood cholinesterase decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":1}],"term":"Blood creatine phosphokinase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":1}],"term":"Blood lactate dehydrogenase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":1}],"term":"Blood urea decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":1}],"term":"C-reactive protein increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":1}],"term":"Gamma-glutamyltransferase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":1,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":1}],"term":"Hyperalbuminaemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":1}],"term":"Hypochloraemia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":1}],"term":"Paralysis recurrent laryngeal nerve"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":1}],"term":"Insomnia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":1,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":1}],"term":"Haematuria"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":1}],"term":"Deep vein thrombosis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":1,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":0,"numAtRisk":1}],"term":"Hypertension"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":1}],"term":"Leukopenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (20.1)","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":5},{"groupId":"EG001","numAffected":0,"numAtRisk":5},{"groupId":"EG002","numAffected":0,"numAtRisk":5},{"groupId":"EG003","numAffected":0,"numAtRisk":3},{"groupId":"EG004","numAffected":1,"numAtRisk":1}],"term":"Hyponatraemia"}],"timeFrame":"Adverse events (AEs) were collected from informed consent signature through study completion (Day 14)."}